Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.42 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16928542 | 0.83 | KCNH2 (0.48) | KCNH2HRH3SIRT2SIRT1ALDH1A1 | |
| SCHEMBL16927920 | 0.81 | HRH3 (0.51) | KCNH2HRH3ALDH1A1RAB9ANPC1 | |
| SCHEMBL16927996 | 0.81 | KDM4E (0.41) | FDFT1ALDH1A1BMP1RAB9ASMN1; SMN2 | |
| SCHEMBL16928197 | 0.81 | SIGMAR1 (0.40) | CHRNB2ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19873510 | 0.77 | TRPV1 (0.36) | ALDH1A1MALT1 | |
| SCHEMBL16928573 | 0.75 | LMNA (0.40) | RAB9ANPC1MAPT | |
| SCHEMBL124262 | 0.75 | CA12 (0.50) | SIRT2SIRT1ALDH1A1POLBRAB9A | |
| SCHEMBL16928191 | 0.74 | SMN1; SMN2 (0.47) | HRH3POLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16928575 | 0.74 | KDM1A (0.45) | CHRNB2HRH3 | |
| SCHEMBL16927986 | 0.73 | LMNA (0.43) | KCNH2HRH3ALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351538-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9700562-B2 | Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | WALTER REED ARMY INST OF RES THE USA AS REPRESENTED BY THE SEC OF THE ARMY ON BEHALF OF THE (US) | 2016-07-28 | — | — | US | disclosed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | CYP3A5, HCCS, COX15 | CHRNB2 4717/4885CHRNA7 4529/4885CHRNA4 4775/4885 |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | HCCS, CYP3A5, COX15 | CHRNB2 4798/4885CHRNA7 4658/4885CHRNA4 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.